Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan
AbstractGene-based vaccines as typified by plasmid DNA vaccines and recombinant viral-vectored vaccines are expected as promising solutions against infectious diseases for which no effective prophylactic vaccines exist such as HIV, dengue virus, Ebola virus and malaria, and for which more improved vaccines are needed such as tuberculosis and influenza virus. Although many preclinical and clinical trials have been conducted to date, no DNA vaccines or recombinant viral-vectored vaccines expressing heterologous antigens for human use have yet been licensed in the U.S., Europe or Japan. In this research, we describe the current regulatory context for gene-based prophylactic vaccines against infectious disease in the U.S., Europe, and Japan. We identify the important considerations, in particular, on the preclinical assessments that would allow these vaccines to proceed to clinical trials, and the differences on the regulatory pathway for the marketing authorization in each region. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Nakayama, Y.; Aruga, A. Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan. Vaccines 2015, 3, 186-202.
Nakayama Y, Aruga A. Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan. Vaccines. 2015; 3(1):186-202.Chicago/Turabian Style
Nakayama, Yoshikazu; Aruga, Atsushi. 2015. "Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan." Vaccines 3, no. 1: 186-202.